Valneva: new positive data for Ixchiq

(CercleFinance.com) - Valneva announces positive data on antibody persistence at 24 months for its single-injection chikungunya vaccine, Ixchiq, having met its primary endpoint with a seroresponse rate of 97%.


Antibody levels remained high and well above the defined seroresponse threshold, thus supporting a long-term immune response, as expected. No safety issues were observed during long-term follow-up, it adds.

This new data will add to that provided for the marketing authorization obtained from the US FDA and for the regulatory approval processes currently underway.


Copyright (c) 2023 CercleFinance.com. All rights reserved.